PARP1-IN-55

PARP1-IN-55 (compound 3f) (48 h) exhibits potent antiproliferative activity and high selectivity against MCF-7 cells, while it shows minimal cytotoxicity against L-02 cells (IC₅₀ > 100 μM) with a selectivity index (SI) exceeding 27^[1].
PARP1-IN-55 (1-10 μM; 48 h) inhibits the expression of intracellular PARP1 in MCF-7 cells in a dose-dependent manner^[1].
PARP1-IN-55 (1-10 μM; 14 days) inhibits the colony formation of MCF-7 cells in a concentration-dependent manner, and completely suppresses the colony formation at 10 μM with little effect on L-02 cells^[1].
PARP1-IN-55 (1-10 μM; 24 h, 48 h) inhibits the migration and invasion of MCF-7 cells in a dose-dependent manner, and significantly downregulates the expression of COL1 in MCF-7 cells at 10 μM^[1].
PARP1-IN-55 (3-10 μM; 48 h) induces apoptosis in MCF-7 cells, which causes early apoptosis at 3 μM and mainly late apoptosis at 5 μM and 10 μM, with minimal apoptotic effect on L-02 cells^[1].
PARP1-IN-55 (1-10 μM) induces a significant dose-dependent increase in intracellular ROS levels, reduces mitochondrial membrane potential (MMP), and disrupts cell membrane integrity as well as induces extensive cell death in MCF-7 cells, while it causes almost no effect on L-02 cells. ^[1].
PARP1-IN-55 (1-10 μM; 24 h) increases the level of γH2AX protein in MCF-7 cells, inhibits the PARP1-mediated DNA damage repair pathway, and causes the accumulation of DNA damage^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.